

A&I

ANÄSTHESIOLOGIE & INTENSIVMEDIZIN

Offizielles Organ: Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e. V. (DGAI)
Berufsverband Deutscher Anästhesistinnen und Anästhesisten e. V. (BDA)

Organ: Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e. V. (DIVI)



Madelung's disease

Metachromatic leukodystrophy

orphan**a**nesthesia

a project of the German Society
of Anaesthesiology and Intensive Care Medicine

SUPPLEMENT NR. 6 | 2023

OrphanAnesthesia –

ein krankheitsübergreifendes Projekt des Wissenschaftlichen Arbeitskreises Kinderanästhesie der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin e.V.

Ziel des Projektes ist die Veröffentlichung von Handlungsempfehlungen zur anästhesiologischen Betreuung von Patientinnen und Patienten mit seltenen Erkrankungen. Damit will OrphanAnesthesia einen wichtigen Beitrag zur Erhöhung der Patientensicherheit leisten.

Patientinnen und Patienten mit seltenen Erkrankungen benötigen für verschiedene diagnostische oder therapeutische Prozeduren eine anästhesiologische Betreuung, die mit einem erhöhten Risiko für anästhesieassoziierte Komplikationen einhergehen. Weil diese Erkrankungen selten auftreten, können Anästhesistinnen und Anästhesisten damit keine Erfahrungen gesammelt haben, sodass für die Planung der Narkose die Einholung weiterer Information unerlässlich ist. Durch vorhandene spezifische Informationen kann die Inzidenz von mit der Narkose assoziierten Komplikationen gesenkt werden. Zur Verfügung stehendes Wissen schafft Sicherheit im Prozess der Patientenversorgung.

Die Handlungsempfehlungen von OrphanAnesthesia sind standardisiert und durchlaufen nach ihrer Erstellung einen Peer-Review-Prozess, an dem eine Anästhesistin bzw. ein Anästhesist sowie eine weitere Krankheitsexpertin bzw. ein weiterer Krankheitsexperte (z. B. Pädiaterin bzw. Pädiater oder Neurologin bzw. Neurologe) beteiligt sind. Das Projekt ist international ausgerichtet, sodass die Handlungsempfehlungen grundsätzlich in englischer Sprache veröffentlicht werden.

Ab Heft 5/2014 werden im monatlichen Rhythmus je zwei Handlungsempfehlungen als Supplement der A&I unter www.ai-online.info veröffentlicht. Als Bestandteil der A&I sind die Handlungsempfehlungen damit auch zitierfähig. Sonderdrucke können gegen Entgelt bestellt werden.

OrphanAnesthesia –

a project of the Scientific Working Group of Paediatric Anaesthesia of the German Society of Anaesthesiology and Intensive Care Medicine

The target of OrphanAnesthesia is the publication of anaesthesia recommendations for patients suffering from rare diseases in order to improve patients' safety. When it comes to the management of patients with rare diseases, there are only sparse evidence-based facts and even far less knowledge in the anaesthetic outcome. OrphanAnesthesia would like to merge this knowledge based on scientific publications and proven experience of specialists making it available for physicians worldwide free of charge.

All OrphanAnesthesia recommendations are standardized and need to pass a peer review process. They are being reviewed by at least one anaesthesiologist and another disease expert (e.g. paediatrician or neurologist) involved in the treatment of this group of patients.

The project OrphanAnesthesia is internationally oriented. Thus all recommendations will be published in English.

Starting with issue 5/2014, we'll publish the OrphanAnesthesia recommendations as a monthly supplement of A&I (Anästhesiologie & Intensivmedizin). Thus they can be accessed and downloaded via www.ai-online.info. As being part of the journal, the recommendations will be quotable. Reprints can be ordered for payment.

Bisher in A&I publizierte Handlungsempfehlungen finden Sie unter:

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu

Find a survey of the recommendations published until now on:

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu



Deutsche Gesellschaft für Anästhesiologie & Intensivmedizin

www.dgai.de



ANÄSTHESIOLOGIE & INTENSIVMEDIZIN

www.ai-online.info

Projektleitung

Prof. Dr. Tino Münster, MHBA

Chefarzt
Klinik für Anästhesie und
operative Intensivmedizin
Krankenhaus Barmherzige
Brüder Regensburg
Prüfeninger Straße 86
93049 Regensburg,
Deutschland

Tel.: 0941 369-2350

E-Mail: Tino.Muenster@barmherzige-regensburg.de



Anaesthesia recommendations for Madelung's disease

Disease name: Madelung's disease

ICD 10: E88.89

Synonyms: Launois-Bensaude syndrome, Benign symmetrical lipomatosis, Multiple symmetrical lipomatosis

Disease summary: Madelung's disease (MD) is a rare disorder affecting predominantly middle-aged males in Mediterranean areas, with a reported male to female ratio ranging from 15:1 to 30:1. It is characterised by diffused symmetrical non-encapsulated lipomas involving the maxillofacial region, neck, shoulders, thorax and head. Masses are normally asymptomatic, causing cosmetic deformity, neck immobility and compression symptoms, such as dyspnoea, dysphagia, dysarthria, hoarseness, and obstructive sleep apnoea. The distribution of lipomas is variable and often indistinguishable from other diseases, such as certain types of morbid obesity, encapsulated lipomas, Cushing syndrome, lymphoma or angiolipomatosis. Therefore, the prevalence may be higher than suggested by literature. The aetiopathogenesis remains unclear. Some factors, such as defects in lipolytic pathways in response to catecholamine, mitochondrial dysfunction, reduction of inducible nitric oxide synthase, and abnormal proliferation of brown fat cells may be involved in the development of the disease. One of the main predisposing factors is alcohol abuse, since approximately 60–90% of MD patients suffer from alcoholism. Chronic alcohol ingestion affects the beta-adrenergic receptors, disrupts lipolysis and affects enzymatic processes in the mitochondria. Because of its association with alcohol consumption, MD may be associated with many comorbidities, such as hepatic disorders, arterial hypertension, dyslipidaemia, diabetes mellitus, polyneuropathy, hypothyroidism, macrocytic anaemia, nephropathy, hyperuricaemia, idiopathic thrombocytopenic purpura or oral cancer. Its diagnosis is established through clinical history and physical examination. Imaging tests complete the diagnosis and exclude the presence of tumours affecting soft tissues. Surgical removal of the adipose masses remains the only effective treatment option. Nevertheless, because of the characteristics of the diffuse and infiltrative lipomas, their complete excision cannot be performed and recurrence is common after surgical treatment. No spontaneous regression of masses has been reported, but alcohol abstinence may delay the progression of the disease and prevent recurrences. The main anaesthetic concern in the treatment of patients with MD is the elevated risk of difficult intubation and a higher risk of postoperative bleeding, because of the difficult haemostasis and the involvement of vessels associated with big masses.

► **Citation:** Becerra-Bolaños A, Prados-Martínez M, Rodríguez-Pérez A: Madelung's disease. *AnästH Intensivmed* 2023;64:S133–S141. DOI: 10.19224/ai2023.S133

Medicine is in progress



Perhaps new knowledge

Every patient is unique

Perhaps the diagnosis is wrong



Find more information on the disease, its centres of reference and patient organisations on Orphanet: www.orpha.net

Typical surgery

Surgical removal of adipose tissue, open lipectomy, liposuction, ultrasound-assisted liposuction, combined lipectomy and liposuction.

Type of anaesthesia

There is no recommendation for either general or regional anaesthesia.

Regional or local anaesthesia can be used in masses of limited size when liposuction is performed.

There is no report of spinal, epidural or caudal anaesthesia. However, as MD rarely affects the lower limbs or the lower body, no difficulties should be found when these types of anaesthesia are possible.

General anaesthesia can be performed using both intravenous or volatile anaesthesia. There is no risk of malignant hyperthermia. Both depolarising and non-depolarising neuromuscular blocking agents have been used. Opioids should be titrated carefully to avoid postoperative respiratory failure.

Patients can be sedated by using benzodiazepines, dexmedetomidine or intravenous anaesthetics. The administration of sedatives should be done carefully, ensuring adequate permeability of the airway and monitoring spontaneous breathing, to avoid respiratory failure.

Necessary additional preoperative testing (beside standard care)

The presence of arterial hypertension can lead to hypertensive cardiomyopathy. Cardiac tests like electrocardiography or echocardiography might be necessary to assess the presence of cardiomyopathies. **Cardiologist assessment should be performed if an active cardiac disease is suspected. Treatment with beta-blockers and statins should be maintained perioperatively.**

Laboratory screening for metabolic syndromes could be recommended to assay fasting glucose, cholesterol, triglycerides, thyroid hormones and uric acid. These patients normally present high levels of high-density lipoprotein cholesterol and low levels of low-density lipoprotein cholesterol. Laboratory tests can also show disorders related to chronic alcohol abuse: elevation of hepatic (ALT, AST, GGT) and pancreatic (amylase, lipase) enzymes, macrocytic anaemia, nephropathy and a higher international normalised ratio. In case of liver disorders, the presence of cirrhosis or syndromes related to hepatic dysfunction, such as hepatorenal syndrome, should be excluded. **The patient should be referred to a haematologist if coagulation disorders are suspected to correct preoperative haemostasis.**

The high incidence of perioperative respiratory failure makes it necessary to perform preoperative chest radiography to exclude acute lung diseases. It might be helpful to exclude the presence of obstructive sleep apnoea syndrome (OSAS) preoperatively using specific questionnaires or polysomnography.

Ultrasonography, CT or MRI can establish the presence of compression or adhesion to adjacent tissue. These imaging tests are useful when patients show compression symptoms such as hoarseness, dyspnoea or dysphagia.

The presence of peripheral polyneuropathy, described as sensory, motor, or autonomic dysfunction, makes it necessary to exclude other causes underlying this neuropathy.

Particular preparation for airway management

Airway management of MD patients is challenging due to the characteristics of the disease. The presence of posterior cervical lipomas provokes neck immobility. Besides, neck fat masses and macroglossia reduce the mouth opening and worsens Mallampati classification. Therefore, airway should be secured awake before inducing general anaesthesia, avoiding the danger of airway obstruction after induction of anaesthesia. **Each department should use a “difficult airway management” algorithm adapted to the knowledge and the skills of the personal and the available instruments and techniques.**

Before airway management, preoxygenation through facial mask using oxygen 100 % for 4–5 minutes is recommended to increase apnoea time, and proceed safely.

Conventional laryngoscopy has been used, attempting an “awake look” after proper topical anaesthesia. Successful use of awake video laryngoscopy has also been reported several times using different types of video laryngoscopes. In patients suffering from giant macroglossia, video laryngoscopy could be complicated. Thus, as difficult airway management guidelines recommend, awake fibre-optic endotracheal intubation remains the gold standard. However, infiltration of the laryngotracheal region by fatty masses will make it difficult to recognise landmarks even if fibre-optic endotracheal intubation is performed. Whenever attempting awake endotracheal intubation, proper sedation should be administered under adequate monitoring and ensuring spontaneous breathing.

When airway management fails, laryngeal mask ventilation could be used as a rescue airway, but an endotracheal tube positioned using a fibre-optic tube guided through laryngeal mask should be used to maintain anaesthesia.

Tracheostomy under local anaesthesia would be difficult due to anterior fat deposits and bleeding risk, which can lead to anterior haematoma that obstructs the airway.

Particular preparation for transfusion or administration of blood products

Postoperative bleeding is frequent in MD patients due to difficult haemostasis and the infiltration of deep tissues. Transfusion of red blood cells or fresh frozen plasma could be indicated to prevent anaemia, maintain haemodynamic stability and promote coagulation if necessary. **The ESA transfusion guidelines should be followed for the indication and use of red blood cell, platelets, and plasma products.**

Particular preparation for anticoagulation

The higher risk of postoperative bleeding makes it necessary to evaluate the risk-benefit ratio of antithrombotic prophylaxis on a case by case basis when there is a possibility of postoperative thrombosis and postoperative immobility. Associated comorbidities may suggest a high risk of thrombosis.

Particular precautions for positioning, transportation and mobilisation

Patients submitted to resection of lipomas located in the dorsal or posterior neck region may require prone decubitus positioning. In these cases, care must be taken to avoid accidental extubation. It is also important to prevent pressure ulcers in long-term interventions.

Interactions of chronic disease and anaesthesia medications

Not reported.

Anaesthetic procedure

Induction of anaesthesia, once the endotracheal tube colocation has already been checked, can be performed using intravenous anaesthetics.

The maintenance of anaesthesia can be safely performed using intravenous and volatile anaesthetics. Propofol, dexmedetomidine, benzodiazepines and sevoflurane have been used without any complication. Opiates should be titrated intraoperatively to avoid postoperative respiratory failure.

Both succinylcholine and non-depolarising neuromuscular blocking agents can be used safely in these patients. No special risk of hyperkalaemia is associated with MD. Antagonisation of neuromuscular blockade is recommended to diminish a postoperative residual neuromuscular block.

Lung-protective ventilation strategies using low tidal volume, positive end-expiratory pressure and intermittent recruitment manoeuvres are recommended. Pulmonary compliance might be reduced in these patients because of the presence of lipomas in the upper thorax. It would be recommended to monitor intraoperative airway pressures.

Multimodal postoperative analgesia, combining nonsteroidal anti-inflammatory drugs, weak opioids and wound infiltration with local anaesthetics is a good option to diminish opiate doses.

Particular or additional monitoring

Standard monitoring, using electrocardiography, peripheral oxygen saturation, end-tidal CO₂ and non-invasive arterial pressure are needed.

In case of lipomas located in the region of the arm where non-invasive blood pressure measurement is performed, invasive arterial pressure might be recommended. Besides, artery canalisation makes it possible to perform gasometric analyses, monitor arterial oxygen and early diagnosis of postoperative respiratory failure and haemodynamic instability.

Due to the high risk of postoperative respiratory failure, monitoring of neuromuscular blockade is recommended to avoid postoperative residual neuromuscular curarisation.

Monitoring the depth of anaesthesia is recommended, since anaesthetic agents can accumulate in fatty masses and prolong anaesthesia time unnecessarily.

Possible complications

Patients with MD have a higher risk of postoperative respiratory failure, due to the presence of masses located in the upper airway. The residual effect of neuromuscular blocking agents, opiates and hypnotic drugs increases the risk of upper airway obstruction.

Because of the infiltrative nature of nonencapsulated lipomas, soft tissue including nerves and vessels can be affected, making it difficult to perform an appropriate haemostasis. The higher risk of bleeding might make it necessary to transfuse red blood cells or fresh frozen plasma. There is a report of postoperative acute respiratory failure secondary to these transfusion requirements. Besides, the higher risk of postoperative bleeding makes the appearance of neck haematomas possible, increasing the risk of respiratory failure.

Postoperative care

Postoperative close monitoring is recommended, due to the high risk of postoperative respiratory failure or bleeding. Intermediate or intensive care unit supervision for 24 hours will detect the appearance of these complications early.

Using postoperative oxygen therapy or noninvasive ventilation (CPAP) may prevent the appearance of postoperative respiratory failure.

Postoperative laboratory tests may diagnose any bleeding disorders that could lead to a higher postoperative bleeding.

Disease-related acute problems and effect on anaesthesia and recovery

There is no acute manifestation of the disease. The risk of acute postoperative renal failure or respiratory failure might be higher in these patients due to the characteristics of the disease.

Ambulatory anaesthesia

Ambulatory anaesthesia (according to common guidelines) should not be performed in MD patients, due to the need for postoperative monitoring and the high rate of postoperative respiratory failure and postoperative bleeding.

Obstetrical anaesthesia

The presence of MD in females is uncommon and there is no report regarding obstetrical anaesthesia in these patients.

References

1. Becerra-Bolaños Á, Valencia L, Cabrera-Ramírez L, Rodríguez-Pérez A. Madelung's Disease and Airway Management. *Anesthesiology* 2019;130:313. DOI: 10.1097/ALN.0000000000002487
2. Brea-García B, Cameselle-Teijeiro J, Couto-González I, Taboada-Suárez A, González-Álvarez E. Madelung's disease: comorbidities, fatty mass distribution, and response to treatment of 22 patients. *Aesthetic Plast Surg* 2013;37:409–416. DOI: 10.1007/s00266-012-9874-5
3. Calvo Hernandez LM, Riol López E, Peña Ferrera L, Apolinario Hidalgo R. Macroglossia in Madelung's disease. *Med Clin (Barc)* 2016;147:e59. DOI: 10.1016/j.medcli.2016.03.045
4. Chen CY, Fang QQ, Wang XF, Zhang MX, Zhao WY, Shi BH, et al. Madelung's Disease: Lipectomy or Liposuction? *Biomed Res Int* 2018;3975974. DOI: 10.1155/2018/3975974
5. Chen HW, Chen HW, Chen HL, Lai CC. Madelung Disease. *Am J Med Sci* 2016;352:54. DOI: 10.1016/j.amjms.2016.06.009
6. Cristofaro MG, Colangeli W, Riccelli U, Giudice M. A case of symmetrical lipomatosis of the tongue presenting as macroglossia. *Ann Ital Chir* 2016;87:S2239253X16025627
7. De Hert S, Imberger G, Carlisle J, Diemunsch P, Fritsch G, Moppett I, et al. Preoperative evaluation of the adult patient undergoing non-cardiac surgery: guidelines from the European Society of Anaesthesiology. *Eur J Anaesthesiol* 2011;28:684–722. DOI: 10.1097/EJA.0b013e3283499e3b
8. Diago LG, Cádiz MJ, Higuera Guerrero J, Sánchez de Merás A. Airway treatment management in a case of Madelung disease or cervical lipomatosis. *Rev Esp Anesthesiol Reanim* 2012;59:60. DOI: 10.1016/j.redar.2012.01.006
9. Esteban Júlvez L, Perelló Aragonés S, Aguilar Bargalló X. Sleep apnea-hypopnea syndrome and multiple symmetrical lipomatosis. *Arch Bronconeumol* 2013;49:86–87. DOI: 10.1016/j.arbres.2012.07.005
10. Fedriani JJ. Two different airway-management strategies in patients with Launois-Bensaude lipomatosis. *Rev Esp Anesthesiol Reanim* 2014;61:353–354. DOI: 10.1016/j.redar.2013.07.008
11. Gao H, Xin ZY, Yin X, Zhang Y, Jin QL, Wen XY. Madelung disease: A case report. *Medicine (Baltimore)* 2019;98:e14116. DOI: 10.1097/MD.00000000000014116
12. García-Miguel FJ, Utrilla C, Montaña E, Alsina FJ, San José JA. Anesthesia in a case of benign symmetrical lipomatosis type Launois-Bensaude. *Rev Esp Anesthesiol Reanim* 1996;43:264–265
13. Gomes da Silva R, Detoffol Braganca R, Ribeiro Costa C, Torres de Melo L, Weiss Telles R, et al. Multiple symmetric lipomatosis. *J Cutan Med Surg* 2011;15:230–235. DOI: 10.2310/7750.2011.10026
14. Jarma Antacle N, Mira Jovells N, Fons Murillo N, Roca Campos P. Patient with Madelung syndrome and difficult-to-treat airway. *Rev Esp Anesthesiol Reanim* 2012;59:58–59. DOI: 10.1016/j.redar.2012.01.005
15. Kozek-Langenecker SA, Ahmed AB, Afshari A, Albaladejo P, Aldecoa C, Barauskas G, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. *Eur J Anaesthesiol* 2017;34:332–395. DOI: 10.1097/EJA.0000000000000630
16. Lopez-Ceres A, Aguilar-Lizarralde Y, Villalobos Sánchez A, Prieto Sánchez E, Valiente Alvarez A. Benign symmetric lipomatosis of the tongue in Madelung's disease. *J Craniomaxillofac Surg* 2006;34:489–493. DOI:10.1016/j.jcms.2006.06.003
17. López-García S, Vizán-Caravaca JR, García-Cortacero E. Madelung's disease. *Med Clin (Barc)* 2019;152:517. DOI: 10.1016/j.medcli.2018.07.022
18. Maximiano LF, Gaspar MT, Nakahira ES. Madelung disease (multiple symmetric lipomatosis). *Autops Case Rep* 2018;8:e2018030. DOI: 10.4322/acr.2018.030
19. Mayo Yáñez M, González Poggioli N, Álvarez-Buylla Blanco M, Herranz González-Botas J. Benign symmetric lipomatosis with lingual involvement: Case report and literature review. *J Stomatol Oral Maxillofac Surg* 2018;119:148–150. DOI: 10.1016/j.jormas.2017.11.006
20. Nisi G, Sisti A. Images in clinical medicine. Madelung's Disease. *N Engl J Med* 2016;374:572. DOI: 10.1056/NEJMim1503861
21. Pinto V, Morselli PG, Tassone D, Piccin O. A case of severe obstructive sleep apnoea in Madelung's disease treated by lateral pharyngoplasty. *J Laryngol Otol* 2017;131:834–837. DOI: 10.1017/S0022215117001062

22. Pinto CI, Carvalho PJ, Correia MM. Madelung's Disease: Revision of 59 Surgical Cases. *Aesthetic Plast Surg* 2017;41:359–368. DOI: 10.1007/s00266-016-0759-x
23. Stopar T, Novak Jankovic V, Casati A. Four different airway-management strategies in patient with Launois-Bensaude syndrome or Madelung's disease undergoing surgical excision of neck lipomatosis with a complicated postoperative course. *J Clin Anesth* 2005;17:300–303. DOI: 10.1016/j.jclinane.2004.07.007
24. Stopar-Pintaric T, Markova L, Tomazevic M, Hodzovic I. An awake videolaryngoscope-assisted intubation in a patient with Madelung disease and a critical airway obstruction. *Minerva Anesthesiol* 2017;83:660–662. DOI: 10.23736/S0375-9393.16.11510-X
25. Suito M, Kitazawa T, Takashimizu I, Ikeda T. Madelung's disease: long-term follow-up. *J Surg Case Rep* 2019;2019:rjy356. DOI: 10.1093/jscr/rjy356
26. Szewc M, Sitarz R, Moroz N, Maciejewski R, Wierzbicki R. Madelung's disease – progressive, excessive, and symmetrical deposition of adipose tissue in the subcutaneous layer: case report and literature review. *Diabetol Metab Syndr Obes* 2018;11:819–825. DOI: 10.2147/DMSO.S181154
27. Tang Y, Wang S, Li P, Tatang X. Airway management and enhanced recovery after surgery pathways in a patient with Madelung's disease. *Minerva Anesthesiol* 2019;85:694–695. DOI: 10.23736/S0375-9393.19.13445-1
28. Torres M, Rodríguez J, Salvatierra B, Gilsanz F. Airway management with the Airtraq in a patient with Launois-Bensaude syndrome. *Rev Esp Anesthesiol Reanim* 2009;56:579–581. DOI: 10.1016/s0034-9356(09)70467-0.

Date last modified: **November 2020**

Authors

Ángel Becerra-Bolaños, Anaesthesiologist, Hospital Universitario de Gran Canaria Doctor Negrín, Spain
angbecbol@gmail.com

Marcos Prados-Martínez, Anaesthesiologist, Hospital Universitario de Gran Canaria Doctor Negrín, Spain
marcospm_9@hotmail.com

Aurelio Rodríguez-Pérez, Anaesthesiologist, Hospital Universitario de Gran Canaria Doctor Negrín, Spain; Universidad de Las Palmas de Gran Canaria, Spain
arodperp@gobiernodecanarias.org

Disclosure The authors have no financial or other competing interest to disclose. This recommendation was unfunded.

Reviewers

Tatjana Stopar-Pintarič, Anaesthesiologist, Ljubljana University Medical Centre/UMC Department of Anaesthesiology and Surgical Intensive Care, Ljubljana, Slovenia
tatjanas38@gmail.com

Jörg Engel, Anaesthesiologist, Clinic for Anaesthesiology and Operative Intensive Care Medicine, Wetzlar, Germany
joerg.engel@lahn-dill-kliniken.de

Disclosure The reviewers have no financial or other competing interest to disclose.

Please note that this recommendation has not been reviewed by an anaesthesiologist and a disease expert but by two anaesthesiologists instead.

Herausgeber



DGAI

Deutsche Gesellschaft
für Anästhesiologie und
Intensivmedizin e.V.
Präsident: Prof. Dr.
B. Pannen, Düsseldorf



BDA

Berufsverband Deutscher
Anästhesistinnen und
Anästhesisten e.V.
Präsident: Prof. Dr.
G. Geldner, Ludwigsburg †

Schriftleitung

Präsident/in der Herausgeberverbände
Gesamtschriftleiter/Editor-in-Chief:
Prof. Dr. Dr. Kai Zacharowski,
ML FRCA FESAIC, Frankfurt
Stellvertretender Gesamtschriftleiter/
Deputy Editor:
Prof. Dr. T. Volk, Homburg/Saar
CME-Schriftleiter/CME-Editor:
Prof. Dr. W. Zink, Ludwigshafen

Redaktionskomitee/Editorial Board

Prof. Dr. G. Beck, Mannheim
Prof. Dr. A. Brinkmann, Heidenheim
Prof. Dr. H. Bürkle, Freiburg
Prof. Dr. B. Ellger, Dortmund
Prof. Dr. K. Engelhard, Mainz
Prof. Dr. M. Fischer, Göppingen
Prof. Dr. U. X. Kaisers, Ulm
Prof. Dr. T. Loop, Freiburg
Prof. Dr. W. Meißner, Jena
Prof. Dr. C. Nau, Lübeck
RAin A. Pfundstein, Nürnberg
Dr. M. Rähmer, Mainz
Prof. Dr. A. Schleppers, Nürnberg
Prof. Dr. M. Thiel, Mannheim
Prof. Dr. F. Wappler, Köln
Prof. Dr. M. Weigand, Heidelberg

Redaktion/Editorial Staff

Carolin Sofia Kopp B.A.
Korrespondenzadresse:
Neuwieder Straße 9 | 90411 Nürnberg |
Deutschland | Tel.: 0911 9337812
E-Mail: anaesth.intensivmed@dgai-ev.de

Verlag & Druckerei

Aktiv Druck & Verlag GmbH

An der Lohwiese 36 |
97500 Ebelsbach | Deutschland
www.aktiv-druck.de



Geschäftsführung

Wolfgang Schröder | Jan Schröder |
Nadja Schwarz
Tel.: 09522 943560 | Fax: 09522 943567
E-Mail: info@aktiv-druck.de

Anzeigen | Vertrieb

Pia Müller | Robert Kux
Tel.: 09522 943570 | Fax: 09522 943577
E-Mail: anzeigen@aktiv-druck.de

Verlagsrepräsentanz

Jürgen Distler
Neuwieder Straße 9 | 90411 Nürnberg
Tel.: 0171 9432534
E-Mail: jdistler@bda-ev.de

Herstellung | Gestaltung

Pia Müller | Robert Kux |
Stefanie Triebert
Tel.: 09522 943570 | Fax: 09522 943577
E-Mail: ai@aktiv-druck.de

Titelbild

Dipl.-Designerin Monique Minde,
Nürnberg

Erscheinungsweise 2023

Der 64. Jahrgang erscheint jeweils zum
Monatsanfang, Heft 7/8 als Doppelausgabe.

Bezugspreise (inkl. Versandkosten):

- Einzelhefte 30,- €
- Jahresabonnement:
 - Europa (ohne Schweiz) 258,- €
(inkl. 7 % MwSt.)
 - Schweiz 266,- €
 - Rest der Welt 241,- €

Mitarbeiter aus Pflege, Labor, Studenten und Auszubildende (bei Vorlage eines entsprechenden Nachweises)

- Europa (ohne Schweiz) 94,- €
(inkl. 7 % MwSt.)
- Schweiz 90,- €
- Rest der Welt 94,- €

Allgemeine Geschäfts- und Liefer- bedingungen

Die allgemeinen Geschäfts- und Liefer-
bedingungen entnehmen Sie bitte dem
Impressum auf www.ai-online.info

Indexed in **Current Contents®/Clinical
Medicine, EMBASE/Excerpta Medica;
Medical Documentation Service;
Research Alert; Sci Search; SUBIS
Current Awareness in Biomedicine;
VINITI: Russian Academy of Science.**

Nachdruck | Urheberrecht

Die veröffentlichten Beiträge sind urhe-
berrechtlich geschützt. Jegliche Art von
Vervielfältigungen – sei es auf mechani-
schem, digitalem oder sonst möglichem
Wege – bleibt vorbehalten. Die Aktiv
Druck & Verlags GmbH ist allein auto-
risiert, Rechte zu vergeben und Sonder-
drucke für gewerbliche Zwecke, gleich
in welcher Sprache, herzustellen. An-
fragen hierzu sind nur an den Verlag zu
richten. Jede im Bereich eines gewerbli-
chen Unternehmens zulässig hergestellte
oder benutzte Kopie dient gewerblichen
Zwecken gem. § 54 (2) UrhG. Die Wie-
dergabe von Gebrauchsnamen, Handels-
namen, Warenbezeichnungen usw. in
dieser Zeitschrift berechtigt auch ohne
besondere Kennzeichnung nicht zu der
Annahme, dass solche Namen im Sinne
der Warenzeichen- und Markenschutz-
Gesetzgebung als frei zu betrachten wä-
ren und daher von jedermann benutzt
werden dürften.

Wichtiger Hinweis

Für Angaben über Dosierungsanwei-
sungen und Applikationsformen kann
vom Verlag und den Herausgebern keine
Gewähr übernommen werden. Derartige
Angaben müssen vom jeweiligen An-
wender im Einzelfall anhand anderer
Literaturstellen auf ihre Richtigkeit über-
prüft werden. Gleiches gilt für berufs-
und verbandspolitische Stellungnahmen
und Empfehlungen.

Allein aus Gründen der besseren Les-
barkeit wird auf die gleichzeitige Ver-
wendung männlicher, weiblicher und
weiterer Sprachformen verzichtet. Sämt-
liche Personenbezeichnungen gelten für
alle Geschlechterformen. Dies impliziert
keinesfalls eine Benachteiligung der je-
weils anderen Geschlechter, sondern ist
als geschlechtsneutral zu verstehen.

Die Beiträge aus der A&I
finden Sie online unter:
www.ai-online.info

**Für Mitglieder der DGAI und/oder
des BDA ist der Bezug der Zeitschrift
im Mitgliedsbeitrag enthalten.**

CONTACT US

Please do not hesitate to contact us. We will be glad to answer and provide further information to you at any time.

.....
Name

.....
First Name

.....
Department / Hospital

.....
Place

.....
Telephone

.....
E-Mail

.....
Date / Signature

Please contact me for further information

I would like to participate in the project

ADDRESS

German Society of Anaesthesiology and
Intensive Care Medicine
Neuwieder Straße 9 | 90411 Nuremberg | Germany
Tel.: +49-911-933780
Email: info@orphananesthesia.eu